PBYI Q3 2022 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$57M+23.5% YoY

Gross Profit

$45M78.1% margin

Operating Income

$2M4.2% margin

Net Income

-$360,000-0.6% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

-4.1%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$199M

Total Liabilities

$177M

Stockholders' Equity

$22M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$46M	+23.5%
Gross Profit	$45M	$36M	+24.0%
Operating Income	$2M	-$9M	+126.7%
Net Income	-$360,000	-$45M	+99.2%

Revenue Segments

Product

$54M95%

Royalty

$3M5%